NASDAQ: CODX - Co-Diagnostics, Inc.

Rentabilität für sechs Monate: -71.99%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Co-Diagnostics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Co-Diagnostics, Inc.

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

weitere details
It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2017-07-12
ISIN US1897631057
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.codiagnostics.com
Цена ао 0.4166
Preisänderung pro Tag: -3.42% (0.3625)
Preisänderung pro Woche: +4.82% (0.334)
Preisänderung pro Monat: -22.54% (0.452)
Preisänderung über 3 Monate: -52.94% (0.744)
Preisänderung über sechs Monate: -71.99% (1.25)
Preisänderung pro Jahr: -69.29% (1.14)
Preisänderung über 3 Jahre: -93.69% (5.55)
Preisänderung über 5 Jahre: -96.7% (10.6)
Preisänderung seit Jahresbeginn: -51.72% (0.7252)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 34.04 1
P/BV 0.3924 10
P/E 0 0
EV/EBITDA -0.4614 0
Gesamt: 4.75

Effizienz

Name Bedeutung Grad
ROA, % -34.09 0
ROE, % -41.08 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0632 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 3068.39 10
Rentabilität Ebitda, % 591.26 10
Rentabilität EPS, % 232.41 10
Gesamt: 10
Weitere Details

Institutionen Volumen Aktie, %
Vanguard Group Inc 1781283 5.7
Renaissance Technologies, LLC 617000 1.97
Blackrock Inc. 501830 1.61
Geode Capital Management, LLC 294422 0.94
Bridgeway Capital Management, Inc. 272900 0.87
Bank Of New York Mellon Corporation 145621 0.47
Kestra Advisory Services, LLC 138607 0.44
Susquehanna International Group, LLP 107699 0.34
State Street Corporation 100647 0.32
Citadel Advisors Llc 96647 0.31



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Dwight H. Egan Chairman & CEO 415.75k 1953 (72 Jahr)
Mr. Brian L. Brown CPA CFO & Company Secretary 338.92k 1976 (49 Jahre)
Dr. Brent C. Satterfield Ph.D. Co-Founder & Member of Scientific Advisory Board 237.5k 1977 (48 Jahre)
Mr. Dan Bohrer CPA Vice President of Finance & Accounting N/A
Mr. Andrew Benson Head of Investor Relations N/A
Dr. Mayuranki Almaula Senior Vice President of Overseas Operations & Strategic Alliances N/A
Mr. Richard David Abbott President N/A 1972 (53 Jahr)
Mr. David Nielsen Chief Operating Officer N/A
Mr. Christopher Thurston Chief Technology Officer N/A
Mr. Cameron Gundry Head of Commercialization LATAM/EUR

Adresse: United States, Salt Lake City. UT, 2401 South Foothill Drive - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.codiagnostics.com